Akribes Biomedical

Executive Summary

Akribes Biomedical is a privately held Austrian biotechnology company focused on developing small molecule therapeutics for chronic wounds, a large and underserved market affecting 10-20 million patients in Europe and the US. Chronic wounds, such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers, represent a significant burden with high morbidity and mortality, yet no new drugs have been approved in over 15 years. The company aims to address this gap with a novel approach that targets the underlying pathophysiology of impaired wound healing. With over 100 billion USD in annual treatment costs globally, there is a substantial commercial opportunity for effective therapies. Akribes is currently in the preclinical stage, advancing its lead candidate toward investigational new drug (IND)-enabling studies. The company's strong scientific foundation and the high unmet medical need position it as a potential leader in wound care innovation.

Upcoming Catalysts (preview)

• Q4 2026Completion of IND-enabling studies and regulatory filing70% success
• Q2 2027Initiation of first-in-human Phase 1 trial60% success
• H1 2027Securing strategic partnership or licensing deal for lead program50% success